Engineering 3D microtissues of pulmonary fibrosis
Ended Project Grant Awarded Last action
- Award ID
- F31HL174133
- Recipient
-
Georgia TECH Research Corp UEI EMW9FC8J3HN4
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $130,141
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date
- Place of performance
- Georgia, USA
Award details come from USAspending.gov.
Description
- Abstract
- Idiopathic pulmonary fibrosis (IPF) is a chronic age-associated disease with a median survival of 3-5 years following diagnosis. Current antifibrotic treatments, pirfenidone and nintedanib, slow the progression of IPF but are insufficient in halting or reversing this disease. While the etiology remains unknown, fibroblast-mediated extracellular matrix (ECM) remodeling leading to the development of fibroblastic foci appears to be a critical component of IPF. The objective of this project is to engineer an in vitro 3D pulmonary microtissue model to explore the contribution of age-associated pathways to fibroblast-mediated ECM remodeling. My previous work generating microtissues supports the feasibility of developing this in vitro 3D pulmonary microtissue model. Additionally, microtissues have been previously used to study cell-matrix interactions including in the context of fibrosis. A main advantage of using the microtissues system to study fibrotic diseases is the ability to assess real-time changes in contractility and cell migration in a medium throughput system. My central hypothesis is that senescence-associated secretory phenotype (sasp) and the development of an apoptosis-resistant phenotype in senescent fibroblasts contribute to ECM remodeling in IPF. The overall objective and hypothesis will be accomplished across three specific aims: 1) engineer pulmonary microtissues using human fibroblasts isolated from IPF and healthy tissues of various ages; 2) evaluate the senescence-associated secretory phenotype of IPF fibroblasts and determine its effects on microtissue remodeling; and 3) assess the development of an apoptosis-resistant phenotype in senescent cells and evaluate the role of FAK in regulating apoptosis. Expected outcomes for this project include: 1) an in vitro pulmonary microtissue model capable of detecting differences in microtissue contractility, stiffness, cell migration, and ECM remodeling; 2) determining the impacts of sasp on ECM remodeling and evaluating the therapeutic benefit of targeting specific components of sasp; and 3) assessing FAK's role in preventing apoptosis in senescent cells and evaluate the therapeutic benefit of FAK inhibition. The results of this study will elucidate the role of fibroblast senescence in the development and progression of pulmonary fibrosis and identify potential druggable targets.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | -$15,501 | |
| Amendment | $0 | |
| Amendment | $1,280 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $1,280 | |
| Amendment | $47,694 | |
| Amendment | $47,694 | |
| Original award | $47,694 |
Quick answers
Who received award F31HL174133?
F31HL174133 was awarded to Georgia TECH Research Corp by National Heart Lung and Blood Institute (National Institutes of Health) on September 22, 2024.
How much is award F31HL174133 worth?
$130,141 has been obligated on F31HL174133.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award